ATE510855T1 - Verwendung eines antikörpers oder eines immunotoxins, der bzw. das selektiv an cd123 bindet zur beeinträchtigung hämatologischer krebs-vorläuferzellen - Google Patents

Verwendung eines antikörpers oder eines immunotoxins, der bzw. das selektiv an cd123 bindet zur beeinträchtigung hämatologischer krebs-vorläuferzellen

Info

Publication number
ATE510855T1
ATE510855T1 AT01923325T AT01923325T ATE510855T1 AT E510855 T1 ATE510855 T1 AT E510855T1 AT 01923325 T AT01923325 T AT 01923325T AT 01923325 T AT01923325 T AT 01923325T AT E510855 T1 ATE510855 T1 AT E510855T1
Authority
AT
Austria
Prior art keywords
cells
leukemia
hematologic cancer
immunotoxin
impair
Prior art date
Application number
AT01923325T
Other languages
English (en)
Inventor
Craig Jordan
Original Assignee
Univ Kentucky Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26882739&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE510855(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Kentucky Res Found filed Critical Univ Kentucky Res Found
Application granted granted Critical
Publication of ATE510855T1 publication Critical patent/ATE510855T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A61K51/1033—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against receptors for cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT01923325T 2000-03-06 2001-03-06 Verwendung eines antikörpers oder eines immunotoxins, der bzw. das selektiv an cd123 bindet zur beeinträchtigung hämatologischer krebs-vorläuferzellen ATE510855T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18712300P 2000-03-06 2000-03-06
US22729500P 2000-08-24 2000-08-24
PCT/US2001/040248 WO2001066139A1 (en) 2000-03-06 2001-03-06 Use of a compound that selectively binds to cd123 to impair hematologic cancer progenitor cell

Publications (1)

Publication Number Publication Date
ATE510855T1 true ATE510855T1 (de) 2011-06-15

Family

ID=26882739

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01923325T ATE510855T1 (de) 2000-03-06 2001-03-06 Verwendung eines antikörpers oder eines immunotoxins, der bzw. das selektiv an cd123 bindet zur beeinträchtigung hämatologischer krebs-vorläuferzellen

Country Status (9)

Country Link
US (5) US6733743B2 (de)
EP (2) EP1263463B1 (de)
JP (5) JP2004509835A (de)
AT (1) ATE510855T1 (de)
AU (2) AU2001250030B2 (de)
CA (3) CA3036031C (de)
ES (1) ES2630761T3 (de)
NZ (1) NZ521255A (de)
WO (1) WO2001066139A1 (de)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE510855T1 (de) * 2000-03-06 2011-06-15 Univ Kentucky Res Found Verwendung eines antikörpers oder eines immunotoxins, der bzw. das selektiv an cd123 bindet zur beeinträchtigung hämatologischer krebs-vorläuferzellen
US7381535B2 (en) * 2002-07-10 2008-06-03 The Board Of Trustees Of The Leland Stanford Junior Methods and compositions for detecting receptor-ligand interactions in single cells
US7393656B2 (en) * 2001-07-10 2008-07-01 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for risk stratification
US7563584B2 (en) 2001-07-10 2009-07-21 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for detecting the activation state of multiple proteins in single cells
US7076472B2 (en) * 2002-08-05 2006-07-11 Edwin Addison Knowledge-based methods for genetic network analysis and the whole cell computer system based thereon
EP1638460A4 (de) * 2003-06-12 2010-05-05 Univ Minnesota Richten von zellen auf zielgewebe oder organe
CA2546465A1 (en) 2003-12-05 2005-06-23 The Board Of Trustees Of The Leland Stanford Junior University Identification, isolation and elimination of cancer stem cells
AU2006206159A1 (en) * 2005-01-24 2006-07-27 Massachusetts Institute Of Technology Method for modeling cell signaling systems by means of bayesian networks
US20070105165A1 (en) * 2005-11-04 2007-05-10 Charles Goolsby Composite profiles of cell antigens and target signal transduction proteins for analysis and clinical management of hematologic cancers
WO2007117423A2 (en) * 2006-03-31 2007-10-18 Cira Discovery Sciences, Inc. Method and apparatus for representing multidimensional data
EP2783700A1 (de) 2006-09-07 2014-10-01 Stemline Therapeutics, Inc. Auf Krebsstammzellen gerichtete Krebstherapie
EP3207941B3 (de) 2006-09-07 2020-08-19 Scott & White Memorial Hospital Verfahren und zusammensetzungen auf basis von diphtherie-toxin-interleukin-konjugaten
US20080118432A1 (en) 2006-09-07 2008-05-22 Ivan Bergstein Monitoring cancer stem cells
EP3255061B1 (de) * 2006-11-03 2021-06-16 The Board of Trustees of the Leland Stanford Junior University Selektive immundepletion einer endogenen stammzellennische zur transplantation
US7989173B2 (en) * 2006-12-27 2011-08-02 The Johns Hopkins University Detection and diagnosis of inflammatory disorders
WO2008127735A1 (en) 2007-04-13 2008-10-23 Stemline Therapeutics, Inc. Il3ralpha antibody conjugates and uses thereof
EP2860247A1 (de) 2007-08-21 2015-04-15 Nodality, Inc. Diagnose-, Prognose- und Behandlungsverfahren
JP2011505386A (ja) * 2007-12-06 2011-02-24 シーエスエル、リミテッド 白血病性幹細胞の阻害方法
US11072655B2 (en) 2008-01-15 2021-07-27 The Board Of Trustees Of The Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
PT3056515T (pt) * 2008-01-15 2019-07-19 Univ Leland Stanford Junior Métodos para manipulação da fagocitose mediada por cd47
CA2711370C (en) 2008-01-15 2017-06-13 The Board Of Trustees Of The Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
GB2474146B (en) * 2008-04-29 2013-04-10 Nodality Inc Methods of determining the health status of an individual
WO2010001989A1 (ja) * 2008-07-03 2010-01-07 協和発酵キリン株式会社 癌幹細胞及び／または癌前駆細胞の減少剤並びに癌の再発及び／または転移の予防剤
US8088822B2 (en) * 2008-07-08 2012-01-03 Ji Zhang Use of fenretinide or bioactive derivatives thereof and pharmaceutical compositions comprising the same
US8399206B2 (en) 2008-07-10 2013-03-19 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
EP2304436A1 (de) 2008-07-10 2011-04-06 Nodality, Inc. Diagnose-, prognose- und behandlungsverfahren
WO2010045651A1 (en) * 2008-10-17 2010-04-22 Nodality, Inc. Methods for analyzing drug response
US9034257B2 (en) * 2008-10-27 2015-05-19 Nodality, Inc. High throughput flow cytometry system and method
US8309306B2 (en) * 2008-11-12 2012-11-13 Nodality, Inc. Detection composition
US20100209929A1 (en) * 2009-01-14 2010-08-19 Nodality, Inc., A Delaware Corporation Multiple mechanisms for modulation of jak/stat activity
US20100204973A1 (en) * 2009-01-15 2010-08-12 Nodality, Inc., A Delaware Corporation Methods For Diagnosis, Prognosis And Treatment
US20100233733A1 (en) * 2009-02-10 2010-09-16 Nodality, Inc., A Delaware Corporation Multiple mechanisms for modulation of the pi3 kinase pathway
US20100209341A1 (en) * 2009-02-18 2010-08-19 Csl Limited Treatment of chronic inflammatory conditions
US20100215644A1 (en) * 2009-02-25 2010-08-26 Nodality, Inc. A Delaware Corporation Analysis of nodes in cellular pathways
US8242248B2 (en) 2009-03-23 2012-08-14 Nodality, Inc. Kits for multiparametric phospho analysis
ES2550639T3 (es) 2009-04-27 2015-11-11 Kyowa Hakko Kirin Co., Ltd. Anticuerpo anti-IL-3Ralfa para su utilización en el tratamiento de un tumor de la sangre
US20100297676A1 (en) * 2009-05-20 2010-11-25 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
US20110059861A1 (en) * 2009-09-08 2011-03-10 Nodality, Inc. Analysis of cell networks
US9459246B2 (en) 2009-09-08 2016-10-04 Nodality, Inc. Induced intercellular communication
CN102665756A (zh) * 2009-10-01 2012-09-12 Csl有限公司 费城染色体阳性白血病的治疗方法
AU2011252851B2 (en) 2010-05-14 2016-10-06 The Board Of Trustees Of The Leland Stanford Junior University Humanized and chimeric monoclonal antibodies to CD47
AU2011267837B2 (en) * 2010-06-15 2016-06-23 Csl Limited Immunotherapeutic method involving CD123 (IL-3Ralpha) antibodies and immunostimulating complex
WO2014130635A1 (en) 2013-02-20 2014-08-28 Novartis Ag Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
AU2015292744C1 (en) 2014-07-21 2021-01-21 Novartis Ag Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
BR112017000939A2 (pt) 2014-07-21 2017-11-14 Novartis Ag tratamento de câncer usando um receptor antigênico quimérico de cll-1
SG10201901157QA (en) 2014-08-12 2019-03-28 Gillies Mcindoe Res Institute Cancer diagnosis and therapy
EP3712171A1 (de) 2014-08-19 2020-09-23 Novartis AG Behandlung von krebs mit einem chimären cd123-antigenrezeptor
ES2688035T3 (es) 2014-08-29 2018-10-30 Gemoab Monoclonals Gmbh Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes
US20180334490A1 (en) 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
AR103488A1 (es) 2015-01-23 2017-05-10 Sanofi Sa Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
JP2018513856A (ja) * 2015-04-08 2018-05-31 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｃｄ１２３に結合する抗体治療剤
CA3172682A1 (en) 2015-04-23 2016-10-27 Nantomics, Llc Cancer neoepitopes
KR20180099768A (ko) 2015-12-30 2018-09-05 노파르티스 아게 증진된 효능을 갖는 면역 이펙터 세포 요법
SG11201807489PA (en) 2016-03-04 2018-09-27 Novartis Ag Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
EP3432924A1 (de) 2016-03-23 2019-01-30 Novartis AG Zellsekretierte minikörper und verwendungen davon
US20230071283A1 (en) 2016-04-15 2023-03-09 Aimee S. Payne Compositions and methods for selective protein expression
TWI790206B (zh) 2016-07-18 2023-01-21 法商賽諾菲公司 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白
SG11201900885VA (en) 2016-08-01 2019-02-27 Novartis Ag Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
WO2018067520A2 (en) 2016-10-04 2018-04-12 Pop Test Oncology Llc Therapeutic agents and methods:
US11535662B2 (en) 2017-01-26 2022-12-27 Novartis Ag CD28 compositions and methods for chimeric antigen receptor therapy
SG11202003415XA (en) 2017-10-18 2020-05-28 Novartis Ag Compositions and methods for selective protein degradation
US20210047405A1 (en) 2018-04-27 2021-02-18 Novartis Ag Car t cell therapies with enhanced efficacy
US20210396739A1 (en) 2018-05-01 2021-12-23 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
US20210213063A1 (en) 2018-05-25 2021-07-15 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
WO2019237035A1 (en) 2018-06-08 2019-12-12 Intellia Therapeutics, Inc. Compositions and methods for immunooncology
IL279367B2 (en) 2018-06-13 2026-05-01 Novartis Ag BCMA chimeric antigen receptors and their uses
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
KR20210099614A (ko) 2018-12-04 2021-08-12 노파르티스 아게 Cd3에 대한 결합 분자 및 이의 용도
AU2019402189B2 (en) 2018-12-20 2023-04-13 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
CA3123519A1 (en) 2019-02-15 2020-08-20 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
EP3924054B1 (de) 2019-02-15 2025-04-02 Novartis AG 3-(1-oxo-5- (piperidin-4-yl)isoindolin-2-yl)piperidin-2,6-dionderivate und ihre verwendungen
WO2020219742A1 (en) 2019-04-24 2020-10-29 Novartis Ag Compositions and methods for selective protein degradation
UY38701A (es) 2019-05-21 2020-12-31 Novartis Ag Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas
AU2020279224B2 (en) 2019-05-21 2024-12-05 Novartis Ag Trispecific binding molecules against BCMA and uses thereof
US20230057071A1 (en) 2019-12-20 2023-02-23 Novartis Ag Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome
US20230332104A1 (en) 2020-06-11 2023-10-19 Novartis Ag Zbtb32 inhibitors and uses thereof
EP4168007A1 (de) 2020-06-23 2023-04-26 Novartis AG Dosierschema mit 3-(1-oxoisoindolin-2-yl)piperidin-2,6-dion-derivaten
EP4188549A1 (de) 2020-08-03 2023-06-07 Novartis AG Heteroarylsubstituierte 3-(1-oxoisoindolin-2-yl)piperidin-2,6-dionderivate und verwendungen davon
KR20250152662A (ko) 2020-12-31 2025-10-23 사노피 NKp46 및 CD123에 결합하는 다기능성 자연살해(NK) 세포 관여자
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
WO2023227790A1 (en) 2022-05-27 2023-11-30 Sanofi Natural killer (nk) cell engagers binding to nkp46 and bcma variants with fc-engineering
WO2024243441A1 (en) 2023-05-24 2024-11-28 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2437213A1 (fr) 1978-09-28 1980-04-25 Cm Ind Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation
EP0044167A3 (de) 1980-07-14 1982-04-21 The Regents Of The University Of California Durch einen Antikörper gerichtetes zytotoxisches Mittel
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
SK282950B6 (sk) 1990-04-24 2003-01-09 Biota Scientific Management Pty Ltd Deriváty alfa-D-neuramínovej kyseliny, spôsob ich prípravy, ich použitie a farmaceutické prípravky na ich báze
DK0578774T3 (da) * 1991-04-05 1999-04-26 Univ Washington Monoklonale antistoffer mod stamcellefaktor-receptorer
US6200547B1 (en) * 1994-01-26 2001-03-13 Ferx Incorporated Magnetically responsive compositions for carrying biologically active substances and methods of production and use
US5532133A (en) 1993-06-02 1996-07-02 New York University Plasmodium vivax blood stage antigens, PvESP-1, antibodies, and diagnostic assays
US6177078B1 (en) 1995-12-29 2001-01-23 Medvet Science Pty Limited Monoclonal antibody antagonists to IL-3
US6120995A (en) * 1997-08-07 2000-09-19 Thomas Jefferson University Compositions that specifically bind to colorectal cancer cells and methods of using the same
ATE510855T1 (de) * 2000-03-06 2011-06-15 Univ Kentucky Res Found Verwendung eines antikörpers oder eines immunotoxins, der bzw. das selektiv an cd123 bindet zur beeinträchtigung hämatologischer krebs-vorläuferzellen

Also Published As

Publication number Publication date
CA2402081A1 (en) 2001-09-13
JP6638171B2 (ja) 2020-01-29
JP2004509835A (ja) 2004-04-02
WO2001066139A9 (en) 2003-02-06
CA2402081C (en) 2015-09-22
US20100093003A1 (en) 2010-04-15
US20150132315A1 (en) 2015-05-14
JP2011201894A (ja) 2011-10-13
NZ521255A (en) 2007-01-26
JP2014074036A (ja) 2014-04-24
ES2630761T3 (es) 2017-08-23
EP1263463B1 (de) 2011-05-25
CA2895884C (en) 2019-04-23
CA2895884A1 (en) 2001-09-13
JP2017226680A (ja) 2017-12-28
EP1263463A1 (de) 2002-12-11
CA3036031C (en) 2021-04-13
EP2329847A3 (de) 2011-10-26
AU5003001A (en) 2001-09-17
US8852551B2 (en) 2014-10-07
US10508150B2 (en) 2019-12-17
AU2001250030B2 (en) 2004-11-25
WO2001066139A1 (en) 2001-09-13
US20030039611A1 (en) 2003-02-27
US7651678B2 (en) 2010-01-26
US6733743B2 (en) 2004-05-11
JP2016056182A (ja) 2016-04-21
WO2001066139A8 (en) 2001-10-11
EP2329847B1 (de) 2016-11-02
EP2329847A2 (de) 2011-06-08
CA3036031A1 (en) 2001-09-13
US20200031942A1 (en) 2020-01-30
US20040197337A1 (en) 2004-10-07

Similar Documents

Publication Publication Date Title
EP2329847A3 (de) Verwendung eines Antikörpers oder eines Immunotoxins, der bzw. das selektiv an CD123 bindet zur Beeinträchtigung hämatologischer Krebs-vorläuferzellen
WO2004018000A3 (en) Compositions and methods for treating cancer using maytansinoid cd44 antibody immonoconjugates and chemotherapeutic agents
MX2010009647A (es) Uso de un anticuerpo anti-cd20 de tipo ii con citotoxicidad celular dependiente del anticuerpo aumentada en combinacion con ciclofosfamida, vincristina y doxorubicina para el tratamiento de linfoma no hodgkiniano.
MX2023004434A (es) Anticuerpos anti-fgfr2 y metodos para usarlos.
WO2005080431A3 (en) Monoclonal antibodies that specifically bind to folate receptor alpha
EA200201042A1 (ru) Способ лечения с использованием конъюгатов лиганд-иммуноген
SG160412A1 (en) Anti-igfr1 antibody therapeutic combinations
SI1545613T1 (sl) Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni
EA200100224A1 (ru) Комбинированная терапия в-клеточных лимфом, предусматривающая введение антитела против cd20
LU91758I2 (fr) Denosumab et ses dérivés pharmaceutiquement acceptables (PROLIA®)
DE69942827D1 (de) Verwendung der epothilons zur behandlung der krebs
ATE494899T1 (de) Zusammensetzung bestehend aus phy906 und chemotherapeutika
EP2399935A3 (de) Anti-CD137-Antikörper als ein Agent bei der Behandlung von Krebs und Glycosylierungvarianten davon
MX2022005221A (es) Conjugados de anticuerpo y farmaco de eribulina anti-mesotelina y metodos de uso.
IL72117A0 (en) Improvements in or relating to immunotoxin conjugates
PH12012502467A1 (en) Novel anti-cd38 antibodies for the treatment of cancer
NO20013444D0 (no) Triazolforbindelser med dopamin-D3-reseptor-affinet
DE60011612D1 (de) Zusammensetzungen und Verfahren zur Krebsbehandlung durch die selektive Hemmung von VEGF
JP2011519864A5 (de)
JP2021518397A5 (de)
MX2007011545A (es) Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr.
ZA200508389B (en) Humanized antibodies to interferon alpha receptor-1(IFNAR-1)
ATE329903T1 (de) Hochgradig lipophile camptothecin-derivate
SI2161283T1 (sl) Sestavki, ki obsegajo protitelesa proti CD79b, konjugirana na sredstvo, ki inhibira rast, ali na citotoksično sredstvo, in postopki za zdravljenje tumorja hematopoetskega izvora
ATE361746T1 (de) Botanischer extrakt mit antikrebs-aktivität enthaltend isoliquiritigenin

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties